Tsuchida Tomoko, Matsuse Hiroto, Machida Ikuko, Kondo Yuki, Saeki Sachiko, Tomari Shinya, Obase Yasushi, Matsuo Nobuko, Shimoda Terufumi, Kohno Shigeru
Second Department of Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.
Allergy Asthma Proc. 2005 Jul-Aug;26(4):287-91.
A few studies compared the additional effects of oral controller medicines on pulmonary function in asthmatic patients on a moderate dose of inhaled steroids. The aim of this study was to compare the additional effects of two oral asthma controllers, a leukotriene receptor antagonist and a sustained released theophylline (Theo), with a moderate dose of inhaled steroid on peak expiratory flow (PEF) and asthma-related symptoms. A total of 67 adult asthmatic patients with PEF < 80% predicted during a 2-week run-in period with 800 microg/day of beclomethasone dipropionate were randomized to receive either pranlukast, 450 mg/day (n = 33), or sustained released Theo, 200 mg/day (n = 34), for 4 weeks. Pranlukast and Theo did not significantly alter the symptom scores, use of rescue beta2-agonist, and daily PEF variability. However, both agents significantly increased both morning and evening PEF compared with the run-in periods. The effects of both medications were comparable. For asthmatic patients even on a moderate dose of inhaled steroids, the addition of either leukotriene receptor antagonist or sustained released Theo does not improve asthma-related symptoms but significantly and equally increases PEF.
一些研究比较了口服控制药物对中度剂量吸入性糖皮质激素治疗的哮喘患者肺功能的附加作用。本研究的目的是比较两种口服哮喘控制药物（一种白三烯受体拮抗剂和一种缓释茶碱（Theo））与中度剂量吸入性糖皮质激素对呼气峰值流速（PEF）和哮喘相关症状的附加作用。共有67例成年哮喘患者在为期2周的导入期内，使用丙酸倍氯米松800微克/天，其PEF<预测值的80%，被随机分为两组，一组接受普仑司特，450毫克/天（n = 33），另一组接受缓释Theo，200毫克/天（n = 34），为期4周。普仑司特和Theo均未显著改变症状评分、急救β2激动剂的使用情况以及每日PEF变异性。然而，与导入期相比，两种药物均显著提高了早晚的PEF。两种药物的效果相当。对于即使使用中度剂量吸入性糖皮质激素的哮喘患者，添加白三烯受体拮抗剂或缓释Theo均不能改善哮喘相关症状，但能显著且同等程度地提高PEF。
